The latest: Wind power equipment maker Xinjiang Goldwind Science & Technology Co. Ltd. (2208.HK; 002202.SZ) said late Tuesday its revenue fell 8.3% in the first quarter of 2022 to 6.4 billion yuan ($962 million). But its profit for the period rose 15.3% to 1.3 billion yuan.

Looking Up: Despite the year-on-year revenue decline, the company’s cash flow from the sale of goods and services rose by 8.4% to 8.2 billion yuan from 7.6 billion yuan in the first quarter of 2021.

Take Note: The profit increase may have come largely from investment income, which more than doubled to 1.3 billion yuan during the quarter compared with 581 million yuan in the year-ago period.

Digging Deeper: Xinjiang Goldwind is one of the world’s leading makers of wind power generation equipment, making it a favorite of big global investors like BlackRock, Citigroup and JPMorgan. The company’s revenue fell by 10% last year from 2020 levels, though its gross profit margin improved notably for the year as it focused on large wind turbines that are typically more profitable. As a result, its profit last year rose 18% to 3.5 billion yuan from 3 billion yuan in 2020. The company made headlines earlier this month when it announced a massive new investment worth nearly $3 billion to develop a deep-sea wind power base with the affluent city of Wenzhou in East China’s Zhejiang province.

Market Reaction: Xinjiang Goldwind’s Hong Kong-listed shares were up nearly 3% late in the Wednesday trading day, while its Shenzhen-listed shares rose by an even stronger 6%. Still, the stock now trades near the bottom of its 52-week range.

Reporting by Doug Young

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

PODCAST: A Bubble Tea IPO Freeze, and a Revenue-less Drug Maker

China's securities regulator puts the brakes on new bubble tea IPOs in Hong Kong. Is this China's latest step to assert its authority over the former British colony? And former drug making highflyer Ascletis has become revenue-less after its earlier drugs fizzled. Now the company is hoping to revive its fortunes with a new weight-loss drug from the same class as Ozempic.